Omeros (OMER)
(Delayed Data from NSDQ)
$3.77 USD
-0.04 (-1.05%)
Updated Jun 12, 2024 04:00 PM ET
After-Market: $3.76 -0.01 (-0.27%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
Omeros Corporation [OMER]
Reports for Purchase
Showing records 281 - 300 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
December 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Q3 Financials Were Uneventful; However, Cash Runway Into 2014 Includes Potentially Transforming Catalysts: Reiterating OUTPERFORM and $32 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
November and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
November and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Insurance Settlement Extends Our Cash Runway Projection Into Q1 2014; Reiterate OUTPERFORM and $32 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
OMS302 Under Formal Regulatory Review in the U.S. and EU; Reiterate OUTPERFORM and Increasing FV to $32
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
October and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Pipeline Update: OMS824/Schizophrenia Phase 2 Initiation Creates Potential Year-End Catalyst; Reiterate OUTPERFORM and $28 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
We See Potential Increased Use of OMS302 with FDA Restrictions for Topicals Used in Eye Surgery; Reiterate OUTPERFORM and Increasing FV to $28
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Submits OMS302 MAA Starting the Clock for Potential Approval in H2:14; Reiterate OUTPERFORM and $18 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Emerging Pharmaceuticals - September and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Q2 Financials Were Not Material; However, Cash Runway Extends Into 2014-Covering Potentially Transforming Catalysts; Reiterating OUTPERFORM & $18 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Omeros Submits OMS302 NDA Starting the Clock for Potential Approval in mid-2014;
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
July And Remaining 2013 Catalysts For Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
June And Remaining 2013 Catalysts For Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Cleared To Begin Phase 2 For OMS824 In Huntington''s
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L